Overview

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.

Phase:

Phase 2

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.
Chiesi Pharmaceuticals Inc.

Treatments:

Flurbiprofen